246 related articles for article (PubMed ID: 34790781)
21. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
[TBL] [Abstract][Full Text] [Related]
22. A new cyclin-dependent kinase-9 inhibitor A09-003 induces apoptosis in acute myeloid leukemia cells with reduction of myeloid cell leukemia sequence-1 protein.
Sim KM; Kim SY; Hwang S; Park S; Lee BR; Nam K; Oh S; Kim I
Chem Biol Interact; 2023 Sep; 382():110554. PubMed ID: 37271215
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
Li Z; Zhang J; Zhou M; Li JL; Qiu QC; Fu JH; Xue SL; Qiu HY
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35103292
[TBL] [Abstract][Full Text] [Related]
24. Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway.
Lin L; Que Y; Lu P; Li H; Xiao M; Zhu X; Li D
Front Pharmacol; 2020; 11():569651. PubMed ID: 33192510
[TBL] [Abstract][Full Text] [Related]
25. Chidamide inhibits t(8;21) AML cell proliferation and AMK1/ETO and C-KIT expression by inhibiting ERK1/2 signaling pathway.
Liu J; Lv N; Zhou L; Li Y; Yu L
Transl Cancer Res; 2020 Feb; 9(2):827-839. PubMed ID: 35117428
[TBL] [Abstract][Full Text] [Related]
26. Chidamide works synergistically with Dasatinib by inducing cell-cycle arrest and apoptosis in acute myeloid leukemia cells.
Deng M; Xiao H; Peng H; Yuan H; Xiao X; Liu S
Mol Cell Biochem; 2023 Apr; 478(4):851-860. PubMed ID: 36107284
[TBL] [Abstract][Full Text] [Related]
27. Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression.
Cao L; Chen Q; Gu H; Li Y; Cao W; Liu Y; Qu J; Hou Y; Chen J; Zhang E; He J; Cai Z
Clin Epigenetics; 2022 Jul; 14(1):84. PubMed ID: 35799216
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
29. Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes.
Jiang J; Wang Y; Liu D; Wang X; Zhu Y; Tong J; Chen E; Xue L; Zhao N; Liang T; Zheng C
Immunotargets Ther; 2023; 12():135-147. PubMed ID: 38026089
[TBL] [Abstract][Full Text] [Related]
30. Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels.
Huang H; Wenbing Y; Dong A; He Z; Yao R; Guo W
Front Oncol; 2019; 9():1276. PubMed ID: 31850196
[TBL] [Abstract][Full Text] [Related]
31. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
32. Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells.
Zhao H; Jiang Y; Lin F; Zhong M; Tan J; Zhou Y; Liu L; Li G; Deng M; Xu B
Exp Hematol Oncol; 2022 May; 11(1):29. PubMed ID: 35581670
[TBL] [Abstract][Full Text] [Related]
33. Combined venetoclax and alvocidib in acute myeloid leukemia.
Bogenberger J; Whatcott C; Hansen N; Delman D; Shi CX; Kim W; Haws H; Soh K; Lee YS; Peterson P; Siddiqui-Jain A; Weitman S; Stewart K; Bearss D; Mesa R; Warner S; Tibes R
Oncotarget; 2017 Dec; 8(63):107206-107222. PubMed ID: 29291023
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract][Full Text] [Related]
35. Disruption of mitochondrial oxidative phosphorylation by chidamide eradicates leukemic cells in AML.
Wang JD; Xu JQ; Long ZJ; Weng JY
Clin Transl Oncol; 2023 Jun; 25(6):1805-1820. PubMed ID: 36899123
[TBL] [Abstract][Full Text] [Related]
36. Chidamide plus decitabine synergistically induces apoptosis of acute myeloid leukemia cells by upregulating
Li Q; Huang JC; Liao DY; Wu Y
Am J Transl Res; 2020; 12(7):3461-3475. PubMed ID: 32774712
[TBL] [Abstract][Full Text] [Related]
37. Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines.
Mao J; Li S; Zhao H; Zhu Y; Hong M; Zhu H; Qian S; Li J
Am J Transl Res; 2018; 10(8):2567-2578. PubMed ID: 30210693
[TBL] [Abstract][Full Text] [Related]
38. BCL-2 inhibitor synergizes with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia.
Yao MY; Wang YF; Zhao Y; Ling LJ; He Y; Wen J; Zheng MY; Jiang HL; Xie CY
Am J Cancer Res; 2022; 12(8):3829-3842. PubMed ID: 36119822
[TBL] [Abstract][Full Text] [Related]
39. Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia.
Zhou C; Wang Z; Yang S; Li H; Zhao L
Front Oncol; 2022; 12():864430. PubMed ID: 35847946
[TBL] [Abstract][Full Text] [Related]
40. Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.
Tregnago C; Benetton M; Da Ros A; Borella G; Longo G; Polato K; Francescato S; Biffi A; Pigazzi M
Front Pharmacol; 2021; 12():820191. PubMed ID: 35153769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
